Figure 1From: The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritisPercentage of patients meeting American College of Rheumatology (ACR) 20, ACR 50, and ACR 70 response criteria after 85 days of therapy with abatacept, LEA29Y, or placebo. Adapted with permission from Moreland and coworkers [2].Back to article page